A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)

Completed · Phase 2 · Has a placebo group

Conditions studied: Neuralgia, Postherpetic

In brief

The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).

Key facts

Study ID

NCT00619476

Run by

XenoPort, Inc.

People needed

376

Starts

2008-02-01

Expected to finish

2009-07-01

Last updated by the study team

2013-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older
• Female subjects are eligible if of non-childbearing potential or not lactating, has a negative pregnancy, and agrees to use one a specified highly effective method for avoiding pregnancy
• Documented medical diagnosis of PHN of with pain present for at least three months from the healing of a herpes zoster rash
• Baseline 24-hour average pain intensity score ≥ 4.0 based on an 11-point PI-NRS
• Provides written informed consent in accordance with all applicable regulatory requirements

You may not qualify if…

• Other chronic pain conditions not associated with PHN. However, the subject will not be excluded if:
• The pain is located at a different region of the body; and
• The pain intensity is not greater than the pain intensity of the PHN; and
• The subject can assess PHN pain independently of other pain
• Is unable to discontinue prohibited medications or non-drug therapies or procedures throughout the duration of the study
• Hepatic impairment defined as ALT or AST > 2x upper limit of normal (ULN), or alkaline phosphatase or bilirubin > 1.5x ULN
• Chronic hepatitis B or C
• Impaired renal function defined as creatinine clearance <60 mL/min or requiring hemodialysis
• Corrected QT (QTc) interval ≥ 450 msec or QTc interval ≥480 msec for patients with Bundle Branch Block
• Uncontrolled hypertension at screen (sitting systolic >160 mmHg and/or sitting diastolic >90 mmHg)
• Current diagnosis of active epilepsy or any active seizure disorder requiring chronic therapy with antiepileptic drugs
• Medical condition or disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of GEn, or, in the investigator's judgment
• Is considered to be clinically significant and may pose a safety concern, or,
• Could interfere with the accurate assessment of safety or efficacy, or,
• Could potentially affect a subject's safety or study outcome
• Meets criteria defined by the DSM-IV-TR for a major depressive episode or for active significant psychiatric disorders within last year
• Depression in remission, with or without antidepressant treatment, may participate, unless stable antidepressant regimen is a prohibited medication
• Antidepressant medication may not be changed or discontinued to meet entry criteria and must be stable for at least three months prior to enrollment
• History of clinically significant drug or alcohol abuse (DSM-IV-TR) or is unable to refrain from substance abuse throughout the study. Benzodiazepines or atypical benzodiazepines as hypnotic sleep agents permitted.
• Currently participating in another clinical study in which the subject is, or will be exposed to an investigational or non-investigational drug or device
• Has participated in a clinical study and was exposed to investigational or non-investigational drug or device:
• Within preceding month for studies unrelated to PHN, or
• Within preceding six months for studies related to PHN
• Treated previously with GEn
• History of allergic or medically significant adverse reaction to investigational products (including gabapentin) or their excipients, acetaminophen or related compounds

Where it is running

• GSK Investigational Site — Northport, Alabama, United States
• GSK Investigational Site — Chandler, Arizona, United States
• GSK Investigational Site — Gilbert, Arizona, United States
• GSK Investigational Site — Litchfield Park, Arizona, United States
• GSK Investigational Site — Scottsdale, Arizona, United States
• GSK Investigational Site — Tucson, Arizona, United States
• GSK Investigational Site — Little Rock, Arkansas, United States
• GSK Investigational Site — Arcadia, California, United States
• GSK Investigational Site — Huntington Park, California, United States
• GSK Investigational Site — New Port Beach, California, United States
• GSK Investigational Site — Northridge, California, United States
• GSK Investigational Site — Oxnard, California, United States
• GSK Investigational Site — Redondo Beach, California, United States
• GSK Investigational Site — Riverside, California, United States
• GSK Investigational Site — San Diego, California, United States
• GSK Investigational Site — San Francisco, California, United States
• GSK Investigational Site — Santa Monica, California, United States
• GSK Investigational Site — Boulder, Colorado, United States
• GSK Investigational Site — Bradenton, Florida, United States
• GSK Investigational Site — Bradenton, Florida, United States
• GSK Investigational Site — Daytona Beach, Florida, United States
• GSK Investigational Site — Hallandale, Florida, United States
• GSK Investigational Site — Hollywood, Florida, United States
• GSK Investigational Site — Naranja, Florida, United States
• GSK Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.